60 related articles for article (PubMed ID: 26757434)
1. Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis.
Siesto G; Cavina R; Romano F; Vitobello D
Am J Clin Oncol; 2018 Mar; 41(3):280-285. PubMed ID: 26757434
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
[TBL] [Abstract][Full Text] [Related]
3. Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival.
Coada CA; Dondi G; Ravegnini G; Di Costanzo S; Tesei M; Fiuzzi E; Di Stanislao M; Giunchi S; Zamagni C; Bovicelli A; Hrelia P; Angelini S; De Iaco P; Perrone AM
J Gynecol Oncol; 2023 Nov; 34(6):e82. PubMed ID: 37743060
[TBL] [Abstract][Full Text] [Related]
4. Upfront debulking surgery or delayed surgery after neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer: Comparison of survival from a noncancer center in India.
Shekhar S; Singh P; Vishnoi JR; Goel S; Pareek P; Sharma C; Goyal M; Yadav G; Jhirwal M; Soni S; Misra S
Indian J Cancer; 2023 Aug; ():. PubMed ID: 38090972
[TBL] [Abstract][Full Text] [Related]
5. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.
Qin M; Jin Y; Ma L; Zhang YY; Pan LY
Oncotarget; 2018 Feb; 9(9):8614-8628. PubMed ID: 29492221
[TBL] [Abstract][Full Text] [Related]
6. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
Filippova OT; Boecking K; Broach V; Gardner GJ; Sonoda Y; Chi DS; Zivanovic O; Long Roche K
Gynecol Oncol; 2024 May; 187():80-84. PubMed ID: 38735143
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.
Sato S; Itamochi H
Ther Adv Med Oncol; 2014 Nov; 6(6):293-304. PubMed ID: 25364394
[TBL] [Abstract][Full Text] [Related]
8. Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers.
Jiang QX; Jiang YX; Wang X; Luo SJ; Zhou R; Linghu H
Clin Chim Acta; 2019 Aug; 495():148-153. PubMed ID: 30885671
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis.
Tzanis AA; Iavazzo C; Hadjivasilis A; Tsouvali H; Antoniou GΑ; Antoniou SA
Oncol Rev; 2022; 16():10605. PubMed ID: 36531160
[No Abstract] [Full Text] [Related]
10. Single Institute Experience with Neo-Adjuvant Chemotherapy and Interval Debulking Surgery in Advanced Endometrial Cancer.
Varshney J; Debnath S; Sharma A; Rawal S; Jain V
Indian J Surg Oncol; 2023 Dec; 14(4):800-808. PubMed ID: 38187853
[TBL] [Abstract][Full Text] [Related]
11. The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients.
Kawahara N; Yamanaka S; Sugimoto S; Kamibayashi J; Nishikawa K; Kawaguchi R; Kimura F
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894429
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
14. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
15. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN; Bookman M; Sehouli J; Miller A; Anderson C; Scambia G; Myers T; Taskiran C; Robison K; Mäenpää J; Willmott L; Colombo N; Thomes-Pepin J; Liontos M; Gold MA; Garcia Y; Sharma SK; Darus CJ; Aghajanian C; Okamoto A; Wu X; Safin R; Wu F; Molinero L; Maiya V; Khor VK; Lin YG; Pignata S
J Clin Oncol; 2021 Jun; 39(17):1842-1855. PubMed ID: 33891472
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation.
Cho JH; Kim S; Song YS
Chin Clin Oncol; 2018 Dec; 7(6):58. PubMed ID: 30509079
[TBL] [Abstract][Full Text] [Related]
19. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
[TBL] [Abstract][Full Text] [Related]
20. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]